BioCryst制药维持2026财年非GAAP运营支出指引于4.5亿至4.7亿美元区间

美股速递05-06

BioCryst制药公司近日重申了其2026财年的财务展望，确认非美国通用会计准则下的运营支出指引仍维持在4.5亿美元至4.7亿美元之间。这一预算框架反映了公司对研发投入与成本管控的平衡策略。

在当前生物科技行业融资环境充满挑战的背景下，明确的支出指引有助于稳定投资者预期。该预算区间将为公司核心管线的临床推进及商业化活动提供资金支持，同时保持财务纪律性。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1136188200?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-05-06 19:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1136188200","market":"us","top_or_hot":-1,"title":"BioCryst制药维持2026财年非GAAP运营支出指引于4.5亿至4.7亿美元区间","media":"美股速递","content":"<p>BioCryst制药公司近日重申了其2026财年的财务展望，确认非美国通用会计准则下的运营支出指引仍维持在4.5亿美元至4.7亿美元之间。这一预算框架反映了公司对研发投入与成本管控的平衡策略。</p>\n<p>在当前生物科技行业融资环境充满挑战的背景下，明确的支出指引有助于稳定投资者预期。该预算区间将为公司核心管线的临床推进及商业化活动提供资金支持，同时保持财务纪律性。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioCryst制药维持2026财年非GAAP运营支出指引于4.5亿至4.7亿美元区间</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioCryst制药维持2026财年非GAAP运营支出指引于4.5亿至4.7亿美元区间\n</h2>\n\n<h4 class=\"meta\">\n\n2026-05-06 19:10 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BioCryst制药公司近日重申了其2026财年的财务展望，确认非美国通用会计准则下的运营支出指引仍维持在4.5亿美元至4.7亿美元之间。这一预算框架反映了公司对研发投入与成本管控的平衡策略。\n在当前生物科技行业融资环境充满挑战的背景下，明确的支出指引有助于稳定投资者预期。该预算区间将为公司核心管线的临床推进及商业化活动提供资金支持，同时保持财务纪律性。</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BCRX","symbol_name":"BioCryst制药","start_time":0,"source_url":"","article_id":"1136188200","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1136188200","pubTimestamp":1778065847,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"BioCryst制药公司近日重申了其2026财年的财务展望，确认非美国通用会计准则下的运营支出指引仍维持在4.5亿美元至4.7亿美元之间。这一预算框架反映了公司对研发投入与成本管控的平衡策略。\n在当前生物科技行业融资环境充满挑战的背景下，明确的支出指引有助于稳定投资者预期。该预算区间将为公司核心管线的临床推进及商业化活动提供资金支持，同时保持财务纪律性。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BCRX":"BioCryst制药","BK4547":"WSB热门概念","BK4139":"生物科技"},"translate_title":"BioCryst Pharmaceuticals Maintains FY2026 Non-GAAP Operating Expense Guidance in Range of $450 Million to $470 Million","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCRX":1},"content_text":"BioCryst制药公司近日重申了其2026财年的财务展望，确认非美国通用会计准则下的运营支出指引仍维持在4.5亿美元至4.7亿美元之间。这一预算框架反映了公司对研发投入与成本管控的平衡策略。\n在当前生物科技行业融资环境充满挑战的背景下，明确的支出指引有助于稳定投资者预期。该预算区间将为公司核心管线的临床推进及商业化活动提供资金支持，同时保持财务纪律性。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1136188200","isCrawlerRequest":true}